title: [Radioimmunotherapy with (90)Y-ibritumomab tiuxetan (Zevalin). Spanish Nuclear Medicine Society].
authors: Comité de Procedimientos de la SEMN, España.
authors: P
authors: P
authors: Bello
authors: M I
authors: MI
authors: Almoguera
authors: M
authors: M
authors: Pajares
authors: C
authors: C
authors: Olivas
authors: L
authors: L
authors: Lapeña
authors: J M
authors: JM
authors: Freire
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology / Q000528:radiation effects; D000075202:Contraindications; D004334:Drug Administration Schedule; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007258:Informed Consent; D016393:Lymphoma, B-Cell / Q000532:radiotherapy*; D008487:Medical History Taking; D016499:Radioimmunotherapy / Q000379:methods*; D011879:Radiotherapy Dosage; D015021:Yttrium Radioisotopes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D018796:Immunoconjugates; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan